Laboratório de Inflamação, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.
J Immunol. 2011 Dec 15;187(12):6518-26. doi: 10.4049/jimmunol.1101806. Epub 2011 Nov 18.
PGD(2) is a key mediator of allergic inflammatory diseases that is mainly synthesized by mast cells, which constitutively express high levels of the terminal enzyme involved in PGD(2) synthesis, the hematopoietic PGD synthase (H-PGDS). In this study, we investigated whether eosinophils are also able to synthesize, and therefore, supply biologically active PGD(2). PGD(2) synthesis was evaluated within human blood eosinophils, in vitro differentiated mouse eosinophils, and eosinophils infiltrating inflammatory site of mouse allergic reaction. Biological function of eosinophil-derived PGD(2) was studied by employing inhibitors of synthesis and activity. Constitutive expression of H-PGDS was found within nonstimulated human circulating eosinophils. Acute stimulation of human eosinophils with A23187 (0.1-5 μM) evoked PGD(2) synthesis, which was located at the nuclear envelope and was inhibited by pretreatment with HQL-79 (10 μM), a specific H-PGDS inhibitor. Prestimulation of human eosinophils with arachidonic acid (10 μM) or human eotaxin (6 nM) also enhanced HQL-79-sensitive PGD(2) synthesis, which, by acting on membrane-expressed specific receptors (D prostanoid receptors 1 and 2), displayed an autocrine/paracrine ability to trigger leukotriene C(4) synthesis and lipid body biogenesis, hallmark events of eosinophil activation. In vitro differentiated mouse eosinophils also synthesized paracrine/autocrine active PGD(2) in response to arachidonic acid stimulation. In vivo, at late time point of the allergic reaction, infiltrating eosinophils found at the inflammatory site appeared as an auxiliary PGD(2)-synthesizing cell population. Our findings reveal that eosinophils are indeed able to synthesize and secrete PGD(2), hence representing during allergic inflammation an extra cell source of PGD(2), which functions as an autocrine signal for eosinophil activation.
PGD(2) 是过敏炎症性疾病的关键介质,主要由肥大细胞合成,这些细胞组成性地表达参与 PGD(2) 合成的终末酶——造血 PGD 合酶 (H-PGDS)。在这项研究中,我们研究了嗜酸性粒细胞是否也能够合成并因此提供具有生物活性的 PGD(2)。在人血液嗜酸性粒细胞、体外分化的小鼠嗜酸性粒细胞和小鼠过敏反应炎症部位浸润的嗜酸性粒细胞中评估了 PGD(2)的合成。通过合成和活性抑制剂研究了嗜酸性粒细胞衍生的 PGD(2)的生物学功能。在非刺激的人循环嗜酸性粒细胞中发现了 H-PGDS 的组成性表达。用 A23187(0.1-5 μM)急性刺激人嗜酸性粒细胞会诱发 PGD(2)合成,该合成位于核膜上,并可被特异性 H-PGDS 抑制剂 HQL-79(10 μM)预处理所抑制。用花生四烯酸(10 μM)或人嗜酸性粒细胞趋化因子(6 nM)预先刺激人嗜酸性粒细胞也增强了 HQL-79 敏感的 PGD(2)合成,该合成通过作用于膜表达的特异性受体(D 前列腺素受体 1 和 2),表现出自分泌/旁分泌能力,触发白三烯 C(4)合成和脂滴生物发生,这是嗜酸性粒细胞激活的标志性事件。体外分化的小鼠嗜酸性粒细胞也可响应花生四烯酸刺激合成旁分泌/自分泌活性 PGD(2)。在体内,在过敏反应的晚期时间点,在炎症部位发现的浸润嗜酸性粒细胞表现为辅助的 PGD(2)合成细胞群体。我们的发现表明,嗜酸性粒细胞确实能够合成和分泌 PGD(2),因此在过敏炎症期间是 PGD(2)的额外细胞来源,其作为嗜酸性粒细胞激活的自分泌信号发挥作用。